FDA Drug Center Rotates Acting Deputy Director: Throckmorton Replaces Goldberger
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting Center Deputy Director Goldberger will return to duties as director of Office of Drug Evaluation IV May 3, when Cardio-Renal Division Director Throckmorton will take his place. Acting Center Director Galson's letter to CDER staff indicates the center will remain without a permanent director for at least six to 12 months.
You may also be interested in...
Throckmorton Named Permanent CDER Deputy Director
Center for Drug Evaluation & Research Acting Deputy Director Douglas Throckmorton has been named to the position on a permanent basis, FDA announced Sept. 22
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.